Adicet Bio Inc (ACET)

Currency in USD
8.410
+0.340(+4.21%)
Closed·
8.250-0.160(-1.90%)
·
ACET is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.7508.605
52 wk Range
6.01017.438
Key Statistics
Prev. Close
8.07
Open
8.15
Day's Range
7.75-8.605
52 wk Range
6.01-17.438
Volume
152.92K
Average Vol. (3m)
125.67K
1-Year Change
-18.4951%
Book Value / Share
15.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACET Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.833
Upside
+314.19%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Adicet Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.833
(+314.19% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy19.00+125.92%-New CoverageMay 04, 2026
Jones Trading
Buy20.00+137.81%-New CoverageApr 06, 2026
H.C. Wainwright
Buy27.00+221.05%50.00MaintainMar 23, 2026
Guggenheim
Buy100.00+1,089.06%128.00MaintainMar 13, 2026
H.C. Wainwright
Buy50.00+494.53%9.00MaintainJan 21, 2026

Adicet Bio Inc SWOT Analysis


Future Catalysts
Anticipate crucial clinical data readouts in 2025 for lupus treatments, potentially validating technology and attracting partnerships
Market Challenges
Navigate the competitive CAR-T landscape as Adicet Bio aims to differentiate its approach in a crowded field of cell therapy developers
Financial Footing
Strong cash position of $125 million extends runway into Q4 2026, supporting ongoing clinical trials despite absence of current revenue
Pipeline Promise
Adicet Bio's innovative gamma-delta T cell therapies for autoimmune diseases and cancer show potential, with clinical trials underway for multiple indications
Read full SWOT analysis

Earnings

Latest Release
Mar 05, 2026
EPS / Forecast
-2.84 / -0.19
Revenue / Forecast
-- / 2.5M
EPS Revisions
Last 90 days

ACET Income Statement

Compare ACET to Peers and Sector

Metrics to compare
ACET
Peers
Sector
Relationship
P/E Ratio
−0.7x−3.8x−0.5x
PEG Ratio
−0.04−0.210.00
Price / Book
0.5x2.6x2.6x
Price / LTM Sales
-5.9x3.2x
Upside (Analyst Target)
163.0%296.3%50.6%
Fair Value Upside
Unlock19.1%7.1%Unlock

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.17M10.88%9.43M
Other Institutional Investors
7.63M71.02%61.61M
Public Companies & Retail Investors
1.95M18.10%15.70M
Total
10.75M100.00%86.75M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Management, L.P.11.00%1,182,6249,544
RA Capital Healthcare Fund, L.P.11.00%1,182,6249,544

People Also Watch

11.870
BNTC
+1.89%
0.2055
ITP
+4.69%
0.5936
XTKG
0.00%
28.37
COAG
-0.67%

FAQ

What Is the Adicet Bio (ACET) Stock Price Today?

The Adicet Bio stock price today is 8.410 USD.

What Stock Exchange Does Adicet Bio Trade On?

Adicet Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Adicet Bio?

The stock symbol for Adicet Bio is "ACET."

What Is the Adicet Bio Market Cap?

As of today, Adicet Bio market cap is 87.370M USD.

What Is Adicet Bio's Earnings Per Share (TTM)?

The Adicet Bio EPS (TTM) is -16.949.

When Is the Next Adicet Bio Earnings Date?

Adicet Bio will release its next earnings report on Mar 05, 2026.

From a Technical Analysis Perspective, Is ACET a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Adicet Bio Stock Split?

Adicet Bio has split 2 times.

How Many Employees Does Adicet Bio Have?

Adicet Bio has 102 employees.

What is the current trading status of Adicet Bio (ACET)?

As of May 14, 2026, Adicet Bio (ACET) is trading at a price of 8.410 USD, with a previous close of 8.070 USD. The stock has fluctuated within a day range of 7.750 USD to 8.605 USD, while its 52-week range spans from 6.010 USD to 17.438 USD.

What Is Adicet Bio (ACET) Price Target According to Analysts?

The average 12-month price target for Adicet Bio is 34.833 USD, with a high estimate of 100 USD and a low estimate of 18 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +314.19% Upside potential.

What Is the ACET Premarket Price?

ACET's last pre-market stock price is 8.150 USD. The pre-market share volume is 80.000, and the stock has decreased by 0.080, or 0.990%.

What Is the ACET After Hours Price?

ACET's last after hours stock price is 8.250 USD, the stock has decreased by -0.160, or -1.900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.